Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe for Chronic Hepatitis C
NCT02971033Phase 2Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ezetimibe in hepatitis C (HCV) (3 arms), sponsored by VA Office of Research & Development. Primary endpoints: Change in Viral Load at 8 weeks and Second Phase Slope at 4 weeks. Started Apr 2018; status: terminated.
02
Drugs
ezetimibe
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02971033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971033.